AltMed, LLC, a Florida based Medical Cannabis Company, Earns Awards for its Products and is Preparing itself to Help Florida Patients
AltMed is applying its unprecedented pharmaceutical, biotech and medical experience to the production of the highest quality cannabis therapies. Already actively harvesting award winning therapies via its Arizona affiliate, AltMed looks forward to bringing that expertise and therapies to Florida patients.
Sarasota, FL – Aug. 4, 2016
AltMed’s affiliate in Arizona recently won 1st and 2nd Prize for Best Medical Cannabis at the prestigious Errl Cup in Arizona, including top honors in the CBD Concentrate category for its “Kayla’s Care”. This is relevant to Florida because CBD Concentrate is the non-hallucinogenic cannabis therapy that the State has been trying to make available for Florida patients for the past two years.
AltMed has moved forward with development and distribution of medical cannabis treatments in legal jurisdictions outside of Florida, including Arizona.
“We have spent the last two years bringing our pharmaceutical industry scientific standards to the development and testing of our products to create the purest and most reliable products on the market in Arizona via our affiliate there,” said Michael Smullen, CEO and co-founder of AltMed. “Because of this experience in pharmaceutical research, testing and production, AltMed is uniquely positioned to offer meaningful therapies for Florida patients following the passage of Amendment 2, the Florida Medical Marijuana Legalization Initiative.”
AltMed has a proven track record in medical cannabis production. Its operations in Arizona currently produce enough medical grade cannabis to serve 1,500 patients a month. Its yield will be capable of serving over 7,000 patients a month later in 2016 with completion of the expansion of its state-of-the-art growing and manufacturing facility with an in-house laboratory.
AltMed is exclusively a medical cannabis company with the research, development and technology expertise, and active proven experience, to provide life changing medical cannabis treatments to patients in Florida.
“We believe that following passage of Amendment 2 and upon securing any necessary licenses or approvals, AltMed will significantly help to fulfill the promise of delivering consistent, high quality medical cannabis treatments to Florida patients,” added Smullen. “Many Florida families are forced to travel out of state, at great expense, to find treatments for their children. We are ready to act once Florida gives the go ahead to deliver medical cannabis treatments to those in need.”
About AltMed LLC
AltMed is an affiliate of Alternative Medical Enterprises, LLC. Alternative Medical Enterprises, LLC, is a fully integrated company that brings pharmaceutical industry precision to the development, production and dispensing of medical cannabinoids.
To the extent any statements made in this press release contain information that is not historical, these statements are forward-looking in nature and merely express our beliefs, expectations or opinions. For example, words such as “may,” “should,” “estimates,” “predicts,” “continues,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” “strategy” and similar expressions are intended to identify forward-looking statements. Such statements are based on current expectations or estimates and involve a number of known and unknown risks and uncertainties that could cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, the following: (i) our ability to implement our business strategy of distributing high quality cannabis products where permissible under applicable law; (ii) availability and cost of additional capital; (iii) our ability to attract, retain and motivate qualified employees and management; (iv) the impact of federal, state or local government regulations; (v) competition in the cannabis industry; (vi) our ability to generate revenues; and (vii) litigation in connection with our business. All forward-looking statements included in this press release and attributable to us or any person acting on our behalf are qualified by this cautionary statement. Forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.
Colin Trethewey/PR MediaNow